GlassScriptPhysician profile
Roberto L Von Sohsten
NPI 1023053279
$15,247.49
in general payments reported to CMS, 2019-2025
35 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $1,371 · 2021: $1,862 · 2022: $3,716 · 2023: $2,521 · 2024: $2,606 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,032 · Education: $36.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,032.26 |
| Education | $36.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,076.77 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $1,604.45 | 2022-2024 | Micra, Cardioinsight, Reveal Linq |
| E.R. Squibb & Sons, L.L.C. | $1,291.31 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $1,262.76 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,148.82 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,068.35 | 2019-2025 | |
| Philips North America LLC | $844.09 | 2022-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Pfizer INC. | $818.05 | 2019-2025 | |
| Abbott Laboratories | $639.83 | 2019-2025 | Aveir |
| Boston Scientific Corporation | $612.39 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Farapulse |
| Astrazeneca Pharmaceuticals LP | $603.81 | 2020-2025 | Farxiga, Wainua |
| Cvrx, INC. | $436.76 | 2019-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $399.07 | 2020-2025 | Onpattro, Amvuttra |
| Impulse Dynamics (USA) INC. | $343.98 | 2022-2025 | Optimizer, Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $296.58 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $287.82 | 2019-2024 | |
| Amarin Pharma, INC. | $261.75 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $253.32 | 2022-2023 | Verquvo |
| Esperion Therapeutics, INC. | $251.82 | 2021-2025 | Nexletol |
| Bridgebio Pharma, INC. | $93.23 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $83.15 | 2025 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $78.71 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $71.43 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $64.19 | 2024 | Arcalyst |
| Novo Nordisk INC | $58.25 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $55.22 | 2025 | Assure Wcd |
| Biosense Webster, INC. | $51.04 | 2022-2023 | Carto 3 |
| Kiniksa Pharmaceuticals, LTD. | $44.62 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $31.75 | 2023 | Opsumit, Uptravi |
| Agepha Pharma Fz LLC | $30.92 | 2024 | Lodoco |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.21 | 2024 | Lifevest |
| Penumbra, INC. | $21.71 | 2022 | |
| Lilly USA, LLC | $16.11 | 2019 | |
| Vifor Pharma, INC. | $14.22 | 2020 | |
| Bardy Diagnostics, INC. | $8.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Von Sohsten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.